Pancreatic Cancer Research

ResearcherQuebec Research and Development CentreActive in the last 2 years

Félix Couture

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-0190-1938; OpenAlex author ID A5055324220. Sources: ClinicalTrials.gov.

Their work

Papers
5
Trials
1
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 trial · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 5

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  4. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  5. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Co-author DOI 10.1007/s12325-016-0327-4↗

Trials 1

  1. Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Study director NCT04862260↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mustapha Ali Tehfe · 4 shared papers, 2016–2026 · strength 0.59
  2. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
  3. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  4. Sharlene Gill · 3 shared papers, 2022–2026 · strength 0.54
  5. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
  6. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
  7. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  8. Jennifer Jane Knox · 3 shared papers, 2022–2026 · strength 0.54
  9. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
  10. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
  11. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  12. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
  13. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
  14. Steve Gallinger · 1 shared paper, 2026 · strength 0.21
  15. Faiyaz Notta · 1 shared paper, 2026 · strength 0.21
  16. George Zogopoulos · 1 shared paper, 2026 · strength 0.21
  17. Vincent Castonguay · 1 shared trial, 2021 · strength 0.20
  18. Anne Gangloff · 1 shared trial, 2021 · strength 0.20
  19. Olivier Dumas · 1 shared trial, 2021 · strength 0.20
  20. Anne-Marie Carreau · 1 shared trial, 2021 · strength 0.20
  21. Nabil G. Seidah · 1 shared trial, 2021 · strength 0.20
  22. Maxime Chénard-Poirier · 1 shared trial, 2021 · strength 0.20
  23. Frédéric Calon · 1 shared trial, 2021 · strength 0.20
  24. Francine Aubin · 1 shared trial, 2021 · strength 0.20
  25. Alfredo Romano · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.